Wen-feng J. Li

Changchun, 130033, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006).

Journal: Liver cancer

Published: August 16, 2025

Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.

Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.

Journal: Frontiers in immunology

Published: July 20, 2025

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective Study.

Journal: Liver cancer

Published: July 18, 2025

Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Journal: Hepatology (Baltimore, Md.)

Published: June 25, 2025

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).

Journal: JHEP reports : innovation in hepatology

Published: April 16, 2025

The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.

The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.

Journal: Frontiers in immunology

Published: March 13, 2025

Letter: Comparison of the Efficacy of Adjuvant PD-1 Inhibitor After Curative Resection for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies.

Letter: Comparison of the Efficacy of Adjuvant PD-1 Inhibitor After Curative Resection for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies.

Journal: Alimentary pharmacology & therapeutics

Published: February 22, 2025

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002).

Journal: Communications medicine

Published: February 05, 2025

Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study.

Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study.

Journal: Liver cancer

Published: January 01, 2025

Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Journal: Hepatology (Baltimore, Md.)

Published: October 07, 2024

Value of ALBI grade on precised estimation liver reserve function of patients with hepatocellular carcinoma

Value of ALBI grade on precised estimation liver reserve function of patients with hepatocellular carcinoma

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: December 06, 2021

The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma

The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: September 30, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026